Cowen & Co. analyst Phil Nadeau maintained a Buy rating on GW Pharma (NASDAQ: GWPH) yesterday and set a price target of $165. The company’s shares opened today at $144.83, close to its 52-week high of $149.95.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.0% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
GW Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $185.
Based on GW Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $62.29 million. In comparison, last year the company had a GAAP net loss of $42.59 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Read More on GWPH:
- GW Pharmaceuticals (GWPH): Cowen Counts on ‘Wide Adoption’ for Epidiolex in Refractory Epilepsies
- GW Pharmaceuticals (GWPH): Epidiolex Will Be Approved Much Before the PDUFA Date, Bets Cantor
- GW Pharmaceuticals (GWPH) Lead Drug’s Green Light Just Around the Corner? Cowen Joins the Conversation
- Why GW Pharmaceuticals (GWPH) Stock Is Posting Strong Gains Today